"description","rationale","instanceType","id","name","uuid:ID","label"
"The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign","StudyDesign_1","Study Design 1","b129d810-0982-40d0-8074-32e0dc167182",""
